Пређи на садржај

Decitabin

С Википедије, слободне енциклопедије
Decitabin
Klinički podaci
DrugsMonografija
Način primeneIntravenozno
Farmakokinetičkipodaci
Poluvreme eliminacije0,5 h
Identifikatori
CAS broj2353-33-5ДаY
ATC kodNone
PubChemCID451668
DrugBankDB01262ДаY
ChemSpider397844ДаY
ChEBICHEBI:50131ДаY
ChEMBLCHEMBL1201129ДаY
Hemijski podaci
FormulaC8H12N4O4
Molarna masa228,205
  • NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
  • InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1ДаY
  • Key:XAUDJQYHKZQPEU-KVQBGUIXSA-NДаY

Decitabinjeorgansko jedinjenje,koje sadrži 8atomaugljenikai imamolekulsku masuod 228,205Da.[1][2][3][4][5][6][7][8][9]

Osobina Vrednost
Broj akceptora vodonika 7
Broj donora vodonika 3
Broj rotacionih veza 2
Particioni koeficijent[10](ALogP) -1,1
Rastvorljivost[11](logS,log(mol/L)) -0,2
Polarna površina[12](PSA,Å2) 120,7
  1. ^Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9.PMID17925555
  2. ^Wijermans PW, Ruter B, Baer MR, Slack JL, Hussain SI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2007 Sep 17;.PMID17881052
  3. ^Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57.PMID20072836
  4. ^Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31.PMID16015501
  5. ^Jabbour E, Issa JP, Garcia-Manero G, Kantar gian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51.PMID18398832
  6. ^Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13.PMID18425818
  7. ^Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4.PMID17023173
  8. ^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035—41.PMC3013709Слободан приступ.PMID21059682.doi:10.1093/nar/gkq1126.уреди
  9. ^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36(Database issue): D901—6.PMC2238889Слободан приступ.PMID18048412.doi:10.1093/nar/gkm958.уреди
  10. ^Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102:3762—3772.doi:10.1021/jp980230o.
  11. ^Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488—1493.PMID11749573.doi:10.1021/ci000392t.уреди
  12. ^Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714—3717.PMID11020286.doi:10.1021/jm000942e.уреди